Christopher A Gravel
Overview
Explore the profile of Christopher A Gravel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai W, Douros A, Gravel C
Pharmacoepidemiol Drug Saf
. 2025 Jan;
34(1):e70102.
PMID: 39810462
Introduction: Masking is a reporting bias where drug safety signals are muffled by elevated reporting of other medications in spontaneous reporting databases. While the impact of masking is often limited,...
2.
DSouza M, Keeshan A, Gravel C, Langlois M, Cooper C
NPJ Vaccines
. 2024 Nov;
9(1):226.
PMID: 39557875
Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type...
3.
Goulet D, Boivin M, Gravel C, Little J, Potter B, Dubois L
Pediatr Obes
. 2024 Oct;
:e13180.
PMID: 39390328
Background/objectives: Few studies have examined the putative mediating role of eating behaviours linking genetic susceptibility and body weight. The goal of this study was to investigate the extent to which...
4.
Gravel C, Bai W, Douros A
Drug Saf
. 2024 May;
47(8):809-819.
PMID: 38703312
Background And Objective: It is unclear which comparator is the most appropriate for bias reduction in disproportionality analyses based on spontaneous reports. We conducted a quasi-quantitative bias analysis using two...
5.
Collins E, Philippe E, Gravel C, Hawken S, Langlois M, Little J
Eur J Clin Invest
. 2023 Dec;
54(4):e14149.
PMID: 38083997
Background: Long COVID is highly heterogeneous, often debilitating, and may last for years after infection. The aetiology of long COVID remains uncertain. Examination of potential serological markers of long COVID,...
6.
Alami A, Villeneuve P, Farrell P, Mattison D, Farhat N, Haddad N, et al.
J Clin Med
. 2023 Aug;
12(15).
PMID: 37568373
Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related...
7.
Fell D, Dimanlig-Cruz S, Torok E, Haberg S, Regan A, Kaufman J, et al.
BMJ Med
. 2023 Jul;
2(1):e000632.
PMID: 37456362
Objective: To assess risk of adverse pregnancy, fetal, and neonatal outcomes after a third dose (first booster dose) of covid-19 vaccine during pregnancy among individuals who had completed both doses...
8.
Alami A, Krewski D, Farhat N, Mattison D, Wilson K, Gravel C, et al.
BMJ Open
. 2023 Jun;
13(6):e065687.
PMID: 37339840
Objective: To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection....
9.
Torok E, Dhinsa T, Dimanlig-Cruz S, Alton G, Sprague A, Dunn S, et al.
Hum Vaccin Immunother
. 2023 May;
19(2):2215150.
PMID: 37249316
During the rapid deployment of COVID-19 vaccines in 2021, safety concerns may have led some pregnant individuals to postpone vaccination until after giving birth. This study aimed to describe temporal...
10.
Gravel C, Douros A
Br J Clin Pharmacol
. 2023 May;
89(9):2671-2676.
PMID: 37226576
Pharmacovigilance studies based on spontaneous reporting systems use disproportionality analysis methods to identify drug-event combinations with higher-than-expected reporting. Enhanced reporting is deemed as a proxy for a detected signal and...